Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
Results: Gabapentin was moderately to mark-edly effective in 30% (15/50) of patients, with statistically nonsignificant differences between patients with bipolar disorder type I, bipolar dis-order type II and NOS, and unipolar major de-pressive disorder. 70% reported side effects, mainly sedation, with 16% of the total sample discontinuing treat Background: Previous studies in predominantly bipolar patients have suggested that gabapentin may be useful in treating mood disorders. This report describes its efficacy and tolerability as an adjunctive agent in treatment-resistant depression. Gabapentin is commonly used off-label in the treatment of psychiatric disorders with success, failure, and controversy. A systematic review of the literature was performed to elucidate the evidence for clinical benefit of gabapentin in psychiatric disorders. Treatment-resistant depression is defined as failure to respond to one or more antidepressant medications at therapeutic doses and occurs in at least 12% of patients with depression. 1, 2 In Respiratory depression: A comprehensive understanding of gabapentin and central nervous system depressants, notably opioids, is critical, given the potential for developing profound respiratory depression. Only two groups have described their experience with gabapentin in either bipolar or unipolar depression (Young et al., 1997, Ghaemi et al., 1998, Young et al., 1999). To our knowledge, this is the first report on the extended adjunctive use of gabapentin in a large cohort of depressed patients resistant to conventional antidepressants. This report describes its efficacy and tolerability as an adjunctive agent in treatment-resistant depression. Methods: A chart review was conducted on 27 outpatients presenting with a depressive disorder in whom gabapentin was added to ongoing treatment with a conventional antidepressant to which patients had not responded after at least 6 weeks. Abstract Risk of dementia following gabapentin prescription in chronic low back pain patients Introduction Gabapentin is widely used to treat chronic pain, but its association with cognitive decline and dementia remains unclear. This study examined whether gabapentin prescription is associated with dementia in adults with chronic low back pain Researchers are exploring new applications of gabapentin for treating treatment-resistant depression and co-morbid conditions like chronic pain syndromes. Moreover, interdisciplinary approaches combining pharmacological and psychotherapeutic strategies are being studied. This toolbox compares pharmacologic options for treatment-resistant depression (TRD) that may be considered if the patient fails to experience adequate response or remission despite optimizing antidepressant therapy. These findings suggest that gabapentin is well-tolerated and may be of adjunctive benefit in the management of treatment-resistant depression. Prospective controlled studies will be necessary to confirm these preliminary observations. Evidence does not support the use of gabapentin for bipolar disorder, major depressive disorder (MDD), posttraumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), stimulant use disorder, or opioid withdrawal. Discover the uses, dosage guidelines, and potential side effects of combining nortriptyline and gabapentin for conditions such as neuropathic pain and treatment-resistant depression. Learn about precautions and drug interactions associated with this combination therapy. Gabapentin is a nerve pain medication and anticonvulsant that has proven to be effective for people who have hard-to-treat depression or other mood disorders. Treatment was uncontrolled and efficacy assessments were retrospective. These findings suggest that gabapentin may be of adjunctive benefit in the management of treatment-resistant depression. Based on the RAND/UCLA Appropriateness Method, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental developed expert consensus guidelines for the management of treatment-resistant depression.
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |